linjc16/ctgov huggingface dataset:
Bioelectrical Impedance Vector Analysis in Cirrhotic Patients

Study Overview
=================
Brief Summary
-----------------
Protein-energy malnutrition and muscle wasting are a common finding among patients with liver cirrhosis. Its prevalence may range from 50-90% depending on the methods used for nutritional assessment. Even stable cirrhotic patients referred as Child A have muscle depletion and the majority of patients classified as Child C have significant depletion. Malnutrition has been shown to be related to several complications of cirrhosis Despite the importance of nutritional status in patient's outcome, there is no gold standard for nutritional assessment. Traditional techniques used in healthy subjects to assess nutritional status cannot be used in cirrhotic patients due especially to ascites and peripheral edema, and altered rates of biochemical markers due to liver failure. Bioelectrical impedance vector analysis has emerged as a useful method to assess body composition and nutritional status especially in patients at the extremes of body weight (fluid overload, excess of adipose tissue, etc.). The aim of this study is to evaluate whether malnutrition assessed by bioelectrical impedance vector analysis is related to the development of hepatic encephalopathy

Official Title
-----------------
Malnutrition Assessed Through Bioelectrical Impedance Vector Analysis is Related to Poor Prognosis in Cirrhosis

Conditions
-----------------
Cirrhosis, Hepatic Encephalopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnose of cirrhosis. Ambulatory patients Exclusion Criteria: Personal history of surgery in the last four weeks Thyroid disorders without replacement therapy Pregnancy Active alcoholism with alcohol ingest in the previous 6 months. Acute or chronic renal failure Hepatic or renal transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hepatic encephalopathy | Assessed by west Haven criteria | 6, 12, 24, 36 and 48 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ascites |  | 6, 12, 24, 36 and 48 months |
Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
Background. Atrial fibrillation is one of the most common complications in the postoperative period of coronary artery bypass grafting (CABG) surgery and usually associated with increased length of hospital stay and higher hospital costs. Among the main mechanisms involved, excessive sympathetic activation, oxidative stress and inflammation are fundamental elements in the pathophysiology of obstructive sleep apnea. Objectives. To evaluate the effects of continuous positive airway pressure (CPAP) in reduction of atrial fibrillation after CABG in patients with obstructive sleep apnea. Methodological procedures: A multicenter randomized controlled study to compare the incidence of atrial fibrillation between the intervention group and the control group, both monitored seven days with Holter.

Official Title
-----------------
Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea: a Multicenter Study

Conditions
-----------------
Atrial Fibrillation, Obstructive Sleep Apnea, Coronary Artery Bypass Grafting

Intervention / Treatment
-----------------
* Device: CPAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: apnea-hypopnea index > 15 events/hour Exclusion Criteria: ejection fraction < 45% chronic atrial fibrillation periprocedural instability (haemodynamic, neurological)

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: CPAP group<br>patients will receive CPAP therapy for the first 7 days after extubation from CABG | Device: CPAP<br>* patients will receive CPAP therapy with Auto-CPAP<br>|
| No Intervention: Control Group<br>Patients will receive usal care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| atrial fibrillation | will be verified by holter monitoring | first 7 days after CABG |
Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis

Study Overview
=================
Brief Summary
-----------------
Adenomyosis was first described as endometrial glands in the myometrium of the uterus. The current definition of adenomyosis is provided in 1972 'the benign invasion of endometrium into the myometrium, producing a diffusely enlarged uterus which microscopically exhibits ectopic non-neoplastic, endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium

Official Title
-----------------
Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis

Conditions
-----------------
Adenomyosis

Intervention / Treatment
-----------------
* Drug: Dienogest
* Drug: Combined Oral Contraceptive


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic adenomyosis irregular menstrual bleeding and dysmenorrhea . Exclusion Criteria: asymptomatic patients - non-lactating patient not desire for pregnancy no hormonal treatment more than 6 month even contraception e.g IUD no focal lesion of uterus (malignancy ,fibroid or adenxal mass )

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study group<br>women will receive dienogest | Drug: Dienogest<br>* oral tablets<br>|
| Active Comparator: control group<br>women used combined oral contraceptive pills | Drug: Combined Oral Contraceptive<br>* oral tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean pain score after receiving treatment | assessment by visual analog scale | 6 months |
Bioavailability and Dosing of a Monosaccharide Supplement in Adults

Study Overview
=================
Brief Summary
-----------------
We are developing an oral supplement of carbohydrates to be added to infant formulas in order to improve brain development, immune function, and overall health of infants and children. After a careful review of what is known about these sugars, there is very little information regarding their use in infants and children, although there is some information in adults and animals. Many of these sugars have been used in a glyco-nutritional supplement in adults and children, with minimal or no reported side effects. We are developing a custom blend of important individual sugars, and need information regarding their dosing and blood concentrations following oral intake of the carbohydrate supplement. Timed blood samples following the carbohydrate supplement will provide us with a better understanding of the most effective dose and the metabolism of these sugars in adults. This will give us the preliminary information we need for developing an oral supplement of special sugars that can be added to infant formulas to help improve brain development and immune function in infants and children.

Official Title
-----------------
Bioavailability and Dosing of an Oral Monosaccharide Supplement in Adults and Effects on Resting Brain Activity

Conditions
-----------------
Healthy Males

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasian (non-hispanic) Male Age 18-28 Regularly eat breakfast Healthy BMI within normal limits (18.5 - 24.9) English speaking Exclusion Criteria: History of smoking, more than occasional alcohol use, or drug use. Chronic medical diagnosis Medications that may interfere with the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutrition, Infant Formula
Institut Paoli Calmettes Lymphoma Database

Study Overview
=================
Brief Summary
-----------------
Database of Institut Paoli-Calmettes patients diagnosed with lymphoma

Official Title
-----------------
Institut Paoli Calmettes Breast Cancer Database

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hodgkin or non-hodgkin lymphoma Exclusion Criteria: Non applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with lymphoma diagnosis<br> | Other: Data collection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of patients | Overall survival of all patients who come in the center | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of patients characteristics | Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies | 10 years |
eHealth for the Elderly

Study Overview
=================
Brief Summary
-----------------
Since internet usage as a complementing element in cancer care is becoming more and more important in oncological routine we launched My-eStEPs (eHealth Strategy for Elderly Patients with Multiple Myeloma) to investigate how specifically elderly patients and their Healthcare Professionals (HCPs) adopt electronic Health (eHealth) support during outpatient treatment. The purpose of this project is to explore how eHealth support influences patients' interaction with their HCPs and how both can benefit from this.

Official Title
-----------------
Multiple Myeloma Patients and Their HCPs Tested eHealth Support

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Other: eHealth platform CANKADO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: multiple myeloma patients treated by oral IMiDs Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of patient's internet use | Evaluated in the following criteria: daily, at least once per week, at least once per month, less than once per month | 3 months | 
| Purpose of patient's internet use | Evaluated in the following criteria: news, online-banking, information collection about products, health-related topics, software downloads, dictionaries | 3 months | 
| Patient's internet use for health-related topics | Evaluated in the following criteria: does the patient use the internet for health-related topics and if yes, for what exactly | 3 months | 
| Patient's technical equipment | The presence of following equipment was evaluated: fixed network telephone, smartphone, internet-enabled computer, notebook, laptop, iPad and tablet ownership. | 3 months | 
| eHealth usage satisfaction | By a structured interview with the patients about their user satisfaction (graded between 1 (best) and 5 (worst)) | 3 months |
24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the short-term mean 24-hour intraocular pressure control, 24-hour blood pressure effect and safety of Latanoprost/Timolol fixed combination given once in the evening with placebo once in the morning versus timolol maleate 0.5% given twice daily in patients with ocular hypertension and primary open-angle glaucoma.

Official Title
-----------------
24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients

Conditions
-----------------
Primary Open Angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: timolol maleate 0.5%
* Drug: latanoprost/timolol fixed combination
* Drug: placebo (artificial tears)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: POAG OHT Exclusion Criteria: Advanced glaucoma Arterial Hypertension

Ages Eligible for Study
-----------------
Minimum Age: 29 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: timolol maleate 0.5%|nan|
|Drug: latanoprost/timolol fixed combination|nan|
|Drug: placebo (artificial tears)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
High-Dose Vitamin D Deficiency in Burn Injury

Study Overview
=================
Brief Summary
-----------------
High dose Vitamin D (50,000IU) therapy may increase bone mineral density/bone mineral content after large burns.

Official Title
-----------------
Use of High-Dose Vitamin D to Treat Vitamin D Deficiency Following Severe Burn Injury in Children I: A Pilot Study

Conditions
-----------------
Burn

Intervention / Treatment
-----------------
* Drug: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5+ yrs Burn size 40% or greater Patient can remain around Shriner Hospital for Children area for 16 weeks Agree to take Vitamin D Exclusion Criteria: Age less than 5yrs Burn size less than 40% Pre-existing bone disease or healing fractures Underlying chronic disease-endocrine or cancer Kidney failure

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Vitamin D administration | Drug: Vitamin D<br>* Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in overall bone health |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burn, vitamin D, nutrition, burn recovery
Does Simethicone Improve Operative Field in Gynecological Operations

Study Overview
=================
Brief Summary
-----------------
Mechanical bowel preparation aims to decrease the volume fecal content in the colon, which thereby decreases the total colony count of bacteria, thus, decreasing peritoneal contamination in case of bowel injury, improving the access to the surgical field and facilitating intraoperative bowel manipulation

Conditions
-----------------
Benign Gynecologic Neoplasm

Intervention / Treatment
-----------------
* Drug: Simethicone
* Drug: Enema


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gynecological operations for benign conditions as hysterectomy, ovarian cystectomy and myomectomy. Exclusion Criteria: History of allergic reaction to study drugs. More than one scar of previous operation. Suspicious of malignancy. Psychiatric disorders.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Simethicone<br>women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation | Drug: Simethicone<br>* Simethicone 40mg oral tablets<br>|
| Active Comparator: Enema<br>women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation. | Drug: Enema<br>* sodium dihydrogen phosphate dihydrate 19.2 gram & disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the degree of small & large bowel preparation |  | intraoperative |
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than those without lymph node metastases. No standard postoperative adjuvant chemotherapy has ever been established.

Official Title
-----------------
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial

Conditions
-----------------
Esophageal Cancer

Intervention / Treatment
-----------------
* Drug: paclitaxel; cisplatin
* Radiation: radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ability to give informed consent histological proof of thoracic esophageal squamous cell carcinoma with negative proximal and distal margins node-positive and pathologic stage M0 Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Patients were enrolled 4 to 10 weeks after surgery Adequate organ function was required in 2 weeks of registration and was defined as: serum creatinine within normal institutional limit, and creatinine clearance (CrCl) ≥60ml/minute. Aspartate aminotransferase and bilirubin<2 times of upper normal institutional limits Exclusion Criteria: prior chemotherapy or concurrent radiation therapy before esophagectomy R1 or R2 resection clinically significant hearing loss or symptomatic peripheral neuropathy during initial examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A<br>chemotherapy and radiotherapy | Drug: paclitaxel; cisplatin<br>* The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.<br>Radiation: radiation<br>* radiation<br>|
| Active Comparator: Arm B<br>radiotherapy | Radiation: radiation<br>* radiation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3 year relapse free survival |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3 year overall survival |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophageal cancer, adjuvant chemotherapy, esophageal surgery, paclitaxel